CORRECTED – UPDATE 1-US panel to review two proposed Avastin uses

(Corrects spelling of docetaxel in third paragraph, not
doxetaxel, as first sent)

* Outside advisers to meet July 20

* Committee will discuss two breast cancer uses

* Panel also to review data on one already approved use

WASHINGTON, May 27 (BestGrowthStock) – A U.S. advisory panel will
meet in July to review two proposed new uses for Roche Holding
AG’s (ROG.VX: ) blockbuster cancer drug Avastin, the Food and
Drug Administration said on Thursday.

The committee of outside experts at a July 20 meeting will
consider applications from Roche unit Genentech to promote
Avastin for certain patients with advanced breast cancer, the
FDA said.

The company is seeking approval of Avastin as a
first-choice treatment for patients with metastatic
HER2-negative breast cancer in combination with the
chemotherapy drug docetaxel, or with other chemotherapy drugs.

Avastin, Roche’s biggest product, already is approved for
treating various types of colon, breast, lung and other
cancers.

The FDA panel also will consider studies Genentech has
submitted to win full approval of Avastin for use with the drug
paclitaxel in some breast cancer patients who have not received
chemotherapy.

That use was cleared based on an abbreviated process that
requires follow-up studies to confirm the drug’s benefits.

Some investors have been nervous that Genentech’s
confirmatory findings were not strong enough and the FDA might
withdraw approval for that use.

Deutsche bank analysts, however, said earlier this month
that recent data could soothe those concerns. Results to be
presented at an upcoming cancer meeting showed Avastin extended
the time patients lived without their cancer growing when used
as a first-choice treatment for advanced breast cancer.

Investing Advice
(Reporting by Lisa Richwine; Editing by Tim Dobbyn)

CORRECTED – UPDATE 1-US panel to review two proposed Avastin uses